Business Description
Neuren Pharmaceuticals Ltd
Description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.96 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 599.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 51.8 | |||||
| 3-Year Book Growth Rate | 33.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.24 | |||||
| 9-Day RSI | 78.83 | |||||
| 14-Day RSI | 78.38 | |||||
| 6-1 Month Momentum % | 2.29 | |||||
| 12-1 Month Momentum % | 69.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 25.77 | |||||
| Quick Ratio | 25.77 | |||||
| Cash Ratio | 23.95 | |||||
| Days Sales Outstanding | 0.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11.04 | |||||
| Net Margin % | 1.26 | |||||
| ROE % | 0.48 | |||||
| ROA % | 0.47 | |||||
| ROIC % | -68.98 | |||||
| ROC (Joel Greenblatt) % | -127.49 | |||||
| ROCE % | -4.21 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 6525 | |||||
| PE Ratio without NRI | 6525 | |||||
| Price-to-Owner-Earnings | 13050 | |||||
| PEG Ratio | 309.24 | |||||
| PS Ratio | 112.5 | |||||
| PB Ratio | 40.53 | |||||
| Price-to-Tangible-Book | 40.53 | |||||
| Price-to-Free-Cash-Flow | 450 | |||||
| Price-to-Operating-Cash-Flow | 450 | |||||
| EV-to-EBIT | -1022.93 | |||||
| EV-to-EBITDA | -1029.34 | |||||
| EV-to-Revenue | 112.89 | |||||
| EV-to-Forward-Revenue | 12.68 | |||||
| EV-to-FCF | 458.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 326.25 | |||||
| Price-to-Graham-Number | 108.75 | |||||
| Price-to-Net-Current-Asset-Value | 40.78 | |||||
| Price-to-Net-Cash | 43.5 | |||||
| Earnings Yield (Greenblatt) % | -0.1 |
How Neuren Pharmaceuticals Ltd (ASX:NEU) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 14.553 | ||
| EPS (TTM) (A$) | 0.002 | ||
| Beta | 2.2 | ||
| Volatility % | 50.52 | ||
| 14-Day RSI | 78.38 | ||
| 14-Day ATR (A$) | 0.700704 | ||
| 20-Day SMA (A$) | 9.889 | ||
| 12-1 Month Momentum % | 69.67 | ||
| 52-Week Range (A$) | 3.33 - 13.46 | ||
| Shares Outstanding (Mil) | 128.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuren Pharmaceuticals Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuren Pharmaceuticals Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neuren Pharmaceuticals Ltd Frequently Asked Questions
What is Neuren Pharmaceuticals Ltd(ASX:NEU)'s stock price today?
The current price of ASX:NEU is A$13.05. The 52 week high of ASX:NEU is A$13.46 and 52 week low is A$3.33.
When is next earnings date of Neuren Pharmaceuticals Ltd(ASX:NEU)?
The next earnings date of Neuren Pharmaceuticals Ltd(ASX:NEU) is .
Does Neuren Pharmaceuticals Ltd(ASX:NEU) pay dividends? If so, how much?
Neuren Pharmaceuticals Ltd(ASX:NEU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
